Mycobacterium kansasii disease in patients infected with human immunodeficiency virus

Rafael E Campo, Carlos E. Campo

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

We evaluated the presenting characteristics, response to therapy, and outcome for 46 patients infected with Mycobacterium kansasii and human immunodeficiency virus (HIV). M. kansasii infection occurred late in HIV disease (mean CD4 lymphocyte count, 52.4/mm3), when most patients had already developed AIDS; 91.3% of the patients had pulmonary involvement, and 21.7% had disseminated disease. Clinical and radiographic findings were consistent with pulmonary disease and had been present for ~4 weeks. Fourteen of the treated patients had disease that resolved or abated (mean survival ±SE, 73.7 weeks ± 14.6 weeks), and 13 had disease that persisted unchanged or worsened (mean survival ±SE, 57.3 ± 15.8 weeks). The outcome was poor for 17 patients who did not receive effective therapy (mean survival ± SE, 14.1 ± 5.3 weeks). M. kansasii infection presents late in the course of HIV disease, and the lung is the organ most frequently involved. Survival is clearly influenced by therapy, and even patients who respond poorly to therapy survive longer than those who are not treated.

Original languageEnglish
Pages (from-to)1233-1238
Number of pages6
JournalClinical Infectious Diseases
Volume24
Issue number6
StatePublished - Jun 25 1997

Fingerprint

Mycobacterium kansasii
HIV
Mycobacterium Infections
Survival
Virus Diseases
Lung
Therapeutics
CD4 Lymphocyte Count
Lung Diseases
Acquired Immunodeficiency Syndrome

ASJC Scopus subject areas

  • Immunology

Cite this

Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. / Campo, Rafael E; Campo, Carlos E.

In: Clinical Infectious Diseases, Vol. 24, No. 6, 25.06.1997, p. 1233-1238.

Research output: Contribution to journalArticle

Campo, Rafael E ; Campo, Carlos E. / Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. In: Clinical Infectious Diseases. 1997 ; Vol. 24, No. 6. pp. 1233-1238.
@article{493b3dd2b0104efba86ae0f955b4d9dd,
title = "Mycobacterium kansasii disease in patients infected with human immunodeficiency virus",
abstract = "We evaluated the presenting characteristics, response to therapy, and outcome for 46 patients infected with Mycobacterium kansasii and human immunodeficiency virus (HIV). M. kansasii infection occurred late in HIV disease (mean CD4 lymphocyte count, 52.4/mm3), when most patients had already developed AIDS; 91.3{\%} of the patients had pulmonary involvement, and 21.7{\%} had disseminated disease. Clinical and radiographic findings were consistent with pulmonary disease and had been present for ~4 weeks. Fourteen of the treated patients had disease that resolved or abated (mean survival ±SE, 73.7 weeks ± 14.6 weeks), and 13 had disease that persisted unchanged or worsened (mean survival ±SE, 57.3 ± 15.8 weeks). The outcome was poor for 17 patients who did not receive effective therapy (mean survival ± SE, 14.1 ± 5.3 weeks). M. kansasii infection presents late in the course of HIV disease, and the lung is the organ most frequently involved. Survival is clearly influenced by therapy, and even patients who respond poorly to therapy survive longer than those who are not treated.",
author = "Campo, {Rafael E} and Campo, {Carlos E.}",
year = "1997",
month = "6",
day = "25",
language = "English",
volume = "24",
pages = "1233--1238",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Mycobacterium kansasii disease in patients infected with human immunodeficiency virus

AU - Campo, Rafael E

AU - Campo, Carlos E.

PY - 1997/6/25

Y1 - 1997/6/25

N2 - We evaluated the presenting characteristics, response to therapy, and outcome for 46 patients infected with Mycobacterium kansasii and human immunodeficiency virus (HIV). M. kansasii infection occurred late in HIV disease (mean CD4 lymphocyte count, 52.4/mm3), when most patients had already developed AIDS; 91.3% of the patients had pulmonary involvement, and 21.7% had disseminated disease. Clinical and radiographic findings were consistent with pulmonary disease and had been present for ~4 weeks. Fourteen of the treated patients had disease that resolved or abated (mean survival ±SE, 73.7 weeks ± 14.6 weeks), and 13 had disease that persisted unchanged or worsened (mean survival ±SE, 57.3 ± 15.8 weeks). The outcome was poor for 17 patients who did not receive effective therapy (mean survival ± SE, 14.1 ± 5.3 weeks). M. kansasii infection presents late in the course of HIV disease, and the lung is the organ most frequently involved. Survival is clearly influenced by therapy, and even patients who respond poorly to therapy survive longer than those who are not treated.

AB - We evaluated the presenting characteristics, response to therapy, and outcome for 46 patients infected with Mycobacterium kansasii and human immunodeficiency virus (HIV). M. kansasii infection occurred late in HIV disease (mean CD4 lymphocyte count, 52.4/mm3), when most patients had already developed AIDS; 91.3% of the patients had pulmonary involvement, and 21.7% had disseminated disease. Clinical and radiographic findings were consistent with pulmonary disease and had been present for ~4 weeks. Fourteen of the treated patients had disease that resolved or abated (mean survival ±SE, 73.7 weeks ± 14.6 weeks), and 13 had disease that persisted unchanged or worsened (mean survival ±SE, 57.3 ± 15.8 weeks). The outcome was poor for 17 patients who did not receive effective therapy (mean survival ± SE, 14.1 ± 5.3 weeks). M. kansasii infection presents late in the course of HIV disease, and the lung is the organ most frequently involved. Survival is clearly influenced by therapy, and even patients who respond poorly to therapy survive longer than those who are not treated.

UR - http://www.scopus.com/inward/record.url?scp=0030960134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030960134&partnerID=8YFLogxK

M3 - Article

C2 - 9195089

AN - SCOPUS:0030960134

VL - 24

SP - 1233

EP - 1238

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -